Updated:
Myovant Sciences Ltd.
Myovant Sciences Ltd. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001679082, and its reported industry...
Overview
Myovant Sciences Ltd. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001679082, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2022-05-11, it reported annual revenue of USD 230,972,000; net income of USD -205,981,000; total assets of USD 520,011,000 for the fiscal period ended 2022-03-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.
Company overview
- Legal name
- Myovant Sciences Ltd.
- Classification
- Company
- Industry (SIC)
- 2834 — Pharmaceutical Preparations
- Headquarters
- London, United Kingdom
- Incorporated in
- CA
- Fiscal year end
- March 31
- SEC CIK
- 0001679082
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2022USD | $231.0M | -$206.0M | $520.0M | $406.7M | -$268.6M | |
| FY2021USD | $59.3M | -$255.1M | $725.0M | $674.5M | $370.6M | |
| FY2020USD | — | -$289.0M | $105.9M | $76.6M | -$221.2M | |
| FY2019USD | — | -$273.6M | $173.0M | $156.1M | -$224.1M |
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| SC 13G | — | SCHEDULE 13G | |
| SC 13G | — | Form SC 13G | |
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 8-K | FORM 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| DEF 14A | DEF 14A |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research Myovant Sciences Ltd. in Altss
Track this company’s investors, transactions and relationships in Altss.